Halozyme Therapeutics, Inc. (0J2O.L)
USD 62.57
(-0.71%)
USD 62.57
(-0.71%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.64 Billion USD | -1.33% |
| 2022 | 1.67 Billion USD | 84.22% |
| 2021 | 907.47 Million USD | 111.59% |
| 2020 | 428.87 Million USD | -9.54% |
| 2019 | 474.1 Million USD | 147.76% |
| 2018 | 191.36 Million USD | -38.58% |
| 2017 | 311.57 Million USD | 5.98% |
| 2016 | 293.99 Million USD | 111.83% |
| 2015 | 138.79 Million USD | 11.37% |
| 2014 | 124.62 Million USD | 2.33% |
| 2013 | 121.78 Million USD | 41.82% |
| 2012 | 85.87 Million USD | 56.54% |
| 2011 | 54.85 Million USD | -22.73% |
| 2010 | 70.99 Million USD | 1.06% |
| 2009 | 70.24 Million USD | 14.81% |
| 2008 | 61.18 Million USD | 33.9% |
| 2007 | 45.69 Million USD | 98.58% |
| 2006 | 23.01 Million USD | 898.98% |
| 2005 | 2.3 Million USD | 45.84% |
| 2004 | 1.57 Million USD | 4117.05% |
| 2003 | 37.45 Thousand USD | 258.95% |
| 2002 | 10.43 Thousand USD | 217.24% |
| 2001 | 3289.00 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.66 Billion USD | 0.86% |
| 2024 Q2 | 1.68 Billion USD | 0.98% |
| 2024 Q3 | 1.66 Billion USD | -0.88% |
| 2023 Q4 | 1.64 Billion USD | 0.36% |
| 2023 Q2 | 1.65 Billion USD | 1.58% |
| 2023 Q1 | 1.63 Billion USD | -2.28% |
| 2023 Q3 | 1.64 Billion USD | -0.96% |
| 2023 FY | 1.64 Billion USD | -1.33% |
| 2022 FY | 1.67 Billion USD | 84.22% |
| 2022 Q4 | 1.67 Billion USD | -5.42% |
| 2022 Q1 | 901.99 Million USD | -0.6% |
| 2022 Q2 | 1.48 Billion USD | 64.99% |
| 2022 Q3 | 1.76 Billion USD | 18.77% |
| 2021 Q2 | 906.11 Million USD | 0.79% |
| 2021 Q1 | 898.98 Million USD | 109.61% |
| 2021 Q4 | 907.47 Million USD | 0.41% |
| 2021 Q3 | 903.74 Million USD | -0.26% |
| 2021 FY | 907.47 Million USD | 111.59% |
| 2020 Q1 | 434.31 Million USD | -8.39% |
| 2020 Q3 | 425.04 Million USD | 0.86% |
| 2020 Q4 | 428.87 Million USD | 0.9% |
| 2020 FY | 428.87 Million USD | -9.54% |
| 2020 Q2 | 421.42 Million USD | -2.97% |
| 2019 Q4 | 474.1 Million USD | 279.28% |
| 2019 FY | 474.1 Million USD | 147.76% |
| 2019 Q3 | 125 Million USD | -20.77% |
| 2019 Q2 | 157.77 Million USD | -6.67% |
| 2019 Q1 | 169.06 Million USD | -11.65% |
| 2018 FY | 191.36 Million USD | -38.58% |
| 2018 Q4 | 191.36 Million USD | -6.55% |
| 2018 Q3 | 204.76 Million USD | -6.85% |
| 2018 Q2 | 219.82 Million USD | -4.59% |
| 2018 Q1 | 230.4 Million USD | -26.05% |
| 2017 Q2 | 286.62 Million USD | 0.47% |
| 2017 FY | 311.57 Million USD | 5.98% |
| 2017 Q1 | 285.26 Million USD | -2.97% |
| 2017 Q4 | 311.57 Million USD | 9.42% |
| 2017 Q3 | 284.76 Million USD | -0.65% |
| 2016 Q4 | 293.99 Million USD | -0.17% |
| 2016 FY | 293.99 Million USD | 111.83% |
| 2016 Q2 | 286.2 Million USD | 2.35% |
| 2016 Q1 | 279.62 Million USD | 101.47% |
| 2016 Q3 | 294.49 Million USD | 2.89% |
| 2015 FY | 138.79 Million USD | 11.37% |
| 2015 Q3 | 126.93 Million USD | 2.52% |
| 2015 Q1 | 121.58 Million USD | -2.44% |
| 2015 Q2 | 123.81 Million USD | 1.84% |
| 2015 Q4 | 138.79 Million USD | 9.34% |
| 2014 FY | 124.62 Million USD | 2.33% |
| 2014 Q2 | 126.75 Million USD | -3.2% |
| 2014 Q3 | 124.68 Million USD | -1.63% |
| 2014 Q1 | 130.93 Million USD | 7.52% |
| 2014 Q4 | 124.62 Million USD | -0.05% |
| 2013 Q4 | 121.78 Million USD | 7.17% |
| 2013 Q2 | 96.24 Million USD | 12.98% |
| 2013 Q1 | 85.18 Million USD | -0.8% |
| 2013 FY | 121.78 Million USD | 41.82% |
| 2013 Q3 | 113.63 Million USD | 18.07% |
| 2012 FY | 85.87 Million USD | 56.54% |
| 2012 Q4 | 85.87 Million USD | 51.21% |
| 2012 Q3 | 56.79 Million USD | 8.15% |
| 2012 Q2 | 52.51 Million USD | -2.13% |
| 2012 Q1 | 53.65 Million USD | -2.19% |
| 2011 Q4 | 54.85 Million USD | 7.17% |
| 2011 FY | 54.85 Million USD | -22.73% |
| 2011 Q2 | 69.45 Million USD | 3.02% |
| 2011 Q1 | 67.41 Million USD | -5.04% |
| 2011 Q3 | 51.18 Million USD | -26.3% |
| 2010 Q1 | 68.35 Million USD | -2.69% |
| 2010 Q2 | 65.6 Million USD | -4.03% |
| 2010 Q3 | 65.38 Million USD | -0.33% |
| 2010 FY | 70.99 Million USD | 1.06% |
| 2010 Q4 | 70.99 Million USD | 8.57% |
| 2009 Q2 | 69.86 Million USD | 7.47% |
| 2009 Q3 | 69.5 Million USD | -0.5% |
| 2009 Q4 | 70.24 Million USD | 1.06% |
| 2009 FY | 70.24 Million USD | 14.81% |
| 2009 Q1 | 65 Million USD | 6.24% |
| 2008 Q3 | 49.86 Million USD | 1.97% |
| 2008 Q2 | 48.9 Million USD | -1.41% |
| 2008 Q1 | 49.6 Million USD | 8.55% |
| 2008 Q4 | 61.18 Million USD | 22.69% |
| 2008 FY | 61.18 Million USD | 33.9% |
| 2007 Q3 | 45.07 Million USD | 35.08% |
| 2007 Q2 | 33.37 Million USD | 1.24% |
| 2007 Q1 | 32.96 Million USD | 43.25% |
| 2007 FY | 45.69 Million USD | 98.58% |
| 2007 Q4 | 45.69 Million USD | 1.36% |
| 2006 Q4 | 23.01 Million USD | 734.59% |
| 2006 Q2 | 2.42 Million USD | -9.93% |
| 2006 Q3 | 2.75 Million USD | 13.66% |
| 2006 FY | 23.01 Million USD | 898.98% |
| 2006 Q1 | 2.69 Million USD | 16.93% |
| 2005 Q3 | 1.81 Million USD | 5.6% |
| 2005 Q1 | 1.92 Million USD | 22.07% |
| 2005 Q2 | 1.71 Million USD | -11.02% |
| 2005 Q4 | 2.3 Million USD | 27.15% |
| 2005 FY | 2.3 Million USD | 45.84% |
| 2004 Q2 | 1.29 Million USD | 67.31% |
| 2004 Q3 | 1.99 Million USD | 53.93% |
| 2004 FY | 1.57 Million USD | 4117.05% |
| 2004 Q4 | 1.57 Million USD | -20.69% |
| 2004 Q1 | 773.24 Thousand USD | 1964.57% |
| 2003 Q4 | 37.45 Thousand USD | 688.15% |
| 2003 Q3 | 4752.00 USD | 0.0% |
| 2003 FY | 37.45 Thousand USD | 258.95% |
| 2003 Q1 | 14.44 Thousand USD | 38.45% |
| 2003 Q2 | 4752.00 USD | -67.11% |
| 2002 Q3 | 4625.00 USD | 39.1% |
| 2002 Q1 | 5082.00 USD | 0.0% |
| 2002 Q2 | 3325.00 USD | -34.57% |
| 2002 Q4 | 10.43 Thousand USD | 125.6% |
| 2002 FY | 10.43 Thousand USD | 217.24% |
| 2001 FY | 3289.00 USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | -164.329% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -3254.201% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -1208.069% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 59.278% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | -167.03% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -13059.901% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -523.062% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 12.729% |
| bluebird bio, Inc. | 424.62 Million USD | -288.452% |
| Blueprint Medicines Corporation | 918.64 Million USD | -79.555% |
| Adicet Bio, Inc. | 37.12 Million USD | -4343.594% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -1336.663% |
| Dynavax Technologies Corporation | 375.02 Million USD | -339.828% |
| Editas Medicine, Inc. | 150.05 Million USD | -999.231% |
| FibroGen, Inc. | 585.72 Million USD | -181.609% |
| Geron Corporation | 146.12 Million USD | -1028.787% |
| Illumina, Inc. | 4.36 Billion USD | 62.22% |
| Insmed Incorporated | 1.66 Billion USD | 0.74% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -557.659% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 36.642% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 91.981% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 52.946% |
| Evolus, Inc. | 209.68 Million USD | -686.631% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | -61.807% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 31.422% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -238.378% |
| Verastem, Inc. | 71.18 Million USD | -2217.148% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 97.605% |
| Zoetis Inc. | 9.29 Billion USD | 82.254% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 96.821% |
| Biogen Inc. | 12.04 Billion USD | 86.306% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -1900.973% |
| Perrigo Company plc | 6.04 Billion USD | 72.696% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 66.461% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -742.689% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -2298.903% |
| Myriad Genetics, Inc. | 312.9 Million USD | -427.153% |
| Waters Corporation | 3.47 Billion USD | 52.554% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -4000.487% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -3304.814% |
| Nektar Therapeutics | 267.04 Million USD | -517.67% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -8118.136% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -4323.099% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -315.211% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -543.118% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 67.97% |
| Imunon, Inc. | 8.53 Million USD | -19236.218% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -4589.02% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -149.62% |
| Homology Medicines, Inc. | 118.53 Million USD | -1291.564% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 76.791% |
| OPKO Health, Inc. | 622.47 Million USD | -164.983% |
| Exelixis, Inc. | 678.44 Million USD | -143.124% |
| TG Therapeutics, Inc. | 169.08 Million USD | -875.522% |
| Incyte Corporation | 1.59 Billion USD | -3.592% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | -39.125% |